阵发性房颤脉冲场消融对比射频消融:BEAT PAROX-AF 试验
BEAT PAROX-AF 是一项欧洲多中心、开放标签、随机对照优效性试验,纳入 289 例药物难治性症状性阵发性房颤患者,比较五叉脉冲场消融(PFA)与 CLOSE 方案射频消融(RFA)的单次手术疗效与安全性。12 个月单次手术成功率 PFA 组为 77.2%,RFA 组为 77.6%,未显示 PFA 优效。PFA 组手术相关严重不良事件数值上更少。
要点
- PFA 与 RFA 在阵发性房颤单次手术 12 个月成功率相当,未显示优效。
- PFA 组手术相关严重不良事件发生率数值上低于 RFA 组。
- RFA 组出现肺静脉狭窄、心包填塞和食管出血,PFA 组未报告死亡、持续性膈神经麻痹或卒中。
核心结论
- 在阵发性房颤患者中,单次五叉 PFA 对比 CLOSE 方案 RFA 未显示更高的 12 个月无心房心律失常复发率,但 PFA 观察到更少的安全性事件。
研究设计与样本
- 欧洲多中心、开放标签、随机对照优效性试验,9 个欧洲中心开展。
- 入组 18–80 岁、有症状、药物难治性阵发性房颤患者,按 1:1 随机分至五叉 PFA 组或 CLOSE 方案 RFA 组。
- 2021 年 12 月至 2024 年 1 月随机 292 例,289 例纳入分析,中位年龄 63.5 岁,58% 为男性。
主要发现
- 手术相关严重不良事件:PFA 组 5 例(3.4%),RFA 组 11 例(7.6%),差值 -3.3%(95%CI -8.4% 至 1.8%)。
- 未出现死亡、持续性膈神经麻痹或卒中。
- RFA 组 2 例肺静脉狭窄大于 70%,12 例大于 50%,2 例心包填塞,1 例食管出血。
关键数值与推荐
- 主要终点定义为消融后 2 个月空白期之后,无持续 30 秒及以上的房性心律失常复发、无心脏复律、无 I/III 类抗心律失常药物恢复使用、无任何再次消融。
临床怎么用
- 对于药物难治性症状性阵发性房颤,PFA 可作为与 CLOSE 方案 RFA 疗效相当的替代消融策略。
- 选择消融能量时可结合安全性事件谱差异和中心操作经验综合判断。
局限性
- 开放标签设计,可能存在操作者终点评估偏倚。
- 样本量和事件数有限,安全性终点的统计学把握度不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: This trial compared single-procedure efficacy and safety of pulsed field ablation (PFA) vs radiofrequency ablation (RFA) in patients with drug-resistant paroxysmal atrial fibrillation (AF). METHODS: BEAT PAROX-AF is a European, multicentre, open-label, randomized, controlled, superiority trial conducted across nine European sites. Eligible patients (aged 18-80 years) with symptomatic, drug-resistant paroxysmal AF were randomized (1:1) to either PFA (pentaspline) or RFA following the CLOSE protocol (contact force sensing catheter and electro-anatomical mapping system). The primary endpoint was the single-procedure success rate after 12 months defined as the absence of ≥30 s atrial arrhythmia recurrence, cardioversion, class I/III antiarrhythmic drug resumption after a 2-month blanking period, or any repeat ablation. RESULTS: From December 2021 to January 2024, 292 patients were randomized and 289 (median age 63.5 years, 58% male) were analysed (PFA n = 145, RFA n = 144). Single-procedure success at 12 months was 112/145 (77.2%) in the PFA group and 111/143 (77.6%) in the RFA group (adjusted difference 0.9%; 95% confidence interval -8.2% to 10.1%; P = .84). Procedure-related serious adverse events occurred in 5 (3.4%) PFA vs 11 (7.6%) RFA patients (difference -3.3% [-8.4%, 1.8%]). No deaths, persistent phrenic palsy nor stroke occurred. In the RFA group, two patients had pulmonary vein stenosis >70% and 12 > 50%, two tamponades, and one oesophageal bleed. CONCLUSIONS: This randomized trial performed in patients with paroxysmal AF did not demonstrate superior efficacy of single-shot PFA vs point-by-point RFA using the CLOSE protocol regarding single-procedure freedom from atrial arrhythmias, despite fewer safety events being observed in this study with PFA.
引用
- Jais, Neuzil, Scherr, et al. Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial. Eur Heart J. 2026. PMID: 41568658. doi:10.1093/eurheartj/ehaf1115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。